SUZHOU, May 6, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the company will first announce the Chinese clinical study data (study number: JSKN003-102) of the HER2 double antagonist conjugate drug JSKN003 to treat HER2-expressing solid tumors at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024, local time.
Subject:Evaluation of safety, pharmacokinetics and efficacy of JSKN003 in patients with advanced solid tumors: a phase I/II clinical study
Summary ID:3031
Report Type and Title:Poster Presentation-Therapies Under Development-Molecular-Targeted Drugs and Tumor Biology
Display time:June 1, 2024, 9:00 a.m. - 12:00 a.m. Central Time
JSKN003 has advantages such as targeting two different epitopes of HER2, glucose-based fixed-point coupling, better serum stability, and a wider treatment window. The Australian Phase I clinical study data released at the American Association for Cancer Research (AACR) annual meeting in April this year showed its good tolerability, safety, and encouraging initial anti-tumor activity. Currently, several clinical studies of JSKN003 are being successfully carried out in Australia and China, and key clinical studies in China to treat advanced HER2 low-expression breast cancer are also being actively promoted.
JSKN003-102 (NCT05744427) is a phase I (dose escalation and dose expansion) and phase II (cohort expansion) study conducted in China. Phase I enrolled patients with histologically proven HER2 expression (IHC ≥ 1+) or patients with HER2 mutant tumors that have failed prior systematic treatment to evaluate the safety, pharmacokinetics (PK), and initial antineoplastic activity of JSKN003 in treating such patients as a single agent, and to determine the maximum tolerable dose (MTD) or phase II recommended dose (RP2D). The results of the Phase I study will be announced at this ASCO conference.
regardingJSKN003
JSKN003 is a novel antibody conjugation drug (ADC) targeting the HER2 double epitope. It was independently developed by Corning Jerry using a unique sugar fixed-point conjugation platform. JSKN003 binds to HER2 on the surface of tumor cells and releases topoisomerase I inhibitors through HER2-mediated cellular endocytosis, thereby exerting an anti-tumor effect. Preclinical studies have shown that JSKN003 has better serum stability, stronger bystander killing effect, and similar tumor killing activity compared to similar drugs, effectively expanding the treatment window. Currently, several clinical studies of JSKN003 are being successfully carried out in Australia and China, and key clinical studies in China to treat advanced HER2 low-expression breast cancer are also being actively promoted.
About Corning Jerry
Corning Jerry is an innovative biopharmaceutical company dedicated to the discovery, development, production and commercialization of world-class anti-tumor drugs to provide patients with innovative biologic therapies. On December 12, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (stock code: 9966.HK).
Corning Jerry has created a biomacromolecular drug development and production technology platform with independent intellectual property rights, such as protein/antibody engineering, antibody screening, and multi-module/multifunctional antibody modification. A product pipeline with significant differentiation advantages and strong international competitiveness has been created, covering innovative anti-tumor drugs such as single-domain antibody/monoclonal antibodies, multi-functional antibodies and antibody conjugates: 1 product, KN035 (the world's first subcutaneous PD- (L) 1 inhibitor, Envolimab injection, product name: Enweida) was approved for marketing in China in 2021, making it a widely accessible drug for cancer patients; 3 products are in late clinical development; HER2 double antibody KN026 was recognized as a breakthrough therapy by China's NMPA. In addition, the company has a rich early development pipeline, and 2 new drug molecules have already entered the clinical research stage.
“Kangda patients, Regis family”. Corning Jerry has always focused on unmet clinical needs and continues to develop safe, affordable, and globally competitive anti-tumor drugs to benefit patients.